Secret To Long, Thick, Dark, Beautiful Eyelashes: Treat Hypotrichosis For Sexy Eyes Minneapolis

www.tcplasticsurgery.com

ALLERGAN ANNOUNCES U.S FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF LATISSE™ -- FIRST AND ONLY TREATMENT APPROVED BY THE FDA FOR HYPOTRICHOSIS OF EYELASHES

Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE™ is a science-based treatment to increase the length, thickness and darkness of eyelashes. Available only through a doctor, LATISSE™ is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE™ users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE™ is required. If use of LATISSE™ is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).

Similar to Allergan´s other medical aesthetic offerings, the benefits of LATISSE™ are derived from scientific evidence, its quality formulation, and medical origin. LATISSE™ was clinically tested in a pivotal Phase III, multi-center, double-masked, placebo-controlled study to assess its safety and efficacy in which all endpoints (improved eyelash prominence, length, thickness and darkness) were met.

Bimatoprost, the active ingredient in LATISSE™, was first approved in 2001 as a medical product to lower intraocular pressure in people with open-angle glaucoma or ocular

hypertension. Patients treated with bimatoprost for this eye condition experienced eyelash growth as a side effect. The long-term safety of bimatoprost for therapeutic use hasbeen recognized by the medical community and well established based on use in 32 clinical trials involving more than 5,700 glaucoma patients and more than 13 years of clinical trial experience. Given the existing and substantial clinical and post-marketing safety data with bimatoprost solution 0.03%, coupled with the positive results from the Phase III LATISSE™ study, LATISSE™ provides patients a clinically meaningful aesthetic benefit with a favorable safety profile.

LATISSE™ will be available in the United States by prescription only and is subject to all U.S. guidelines applicable to dispensing a prescription product. Based on today´s FDA approval, Allergan expects to launch the product nationwide in the first quarter of 2009. Doctors and consumers are encouraged to visit www.latisse.com for further product and prescribing information.

Important LATISSE™ Safety Information

LATISSE™ solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. DO NOT APPLY to the lower eyelid. If you are using LUMIGANR or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use LATISSE™ under the close supervision of your doctor. LATISSE™ use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE™ use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent. It is possible for hair growth to occur in other areas of your skin that LATISSE™ frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using LATISSE™. The most common side effects after using LATISSE™ solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients.

If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your doctor´s advice concerning the continued use of LATISSE™ solution. Full prescribing information is available at www.latisse.com and www.allergan.com.

About Allergan, Inc.

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential - to see more clearly, move more freely, express themselves more fully. The Company employs more than 8,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

Allergan Medical, a division of Allergan, Inc., offers the most comprehensive, science-based, aesthetic product offerings under its Total Facial Rejuvenation™ portfolio, including BOTOXR Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical also offers the industry's widest range of silicone gel-filled and saline-filled breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment.

Please call our friendly staff to set up a complimentary consultation.

Dr. Joseph M. Gryskiewicz

info@tcplasticsurgery.com

www.tcplasticsurgery.com

Gryskiewicz Twin Cities Cosmetic Surgery

Joseph M. Gryskiewicz, MD, FACS

info@tcplasticsurgery.com

Edina-Centennial Lakes Medical Center

7373 France Avenue South

Suite 208

Burnsville,MN 55337

Phone: (952) 842-1000

Fax: (952) 435-6287

Burnsville-Ridgeview Medical Building

303 E Nicollet Boulevard

Suite330

Edina, MN 55435

Phone: (952) 435-0177

Fax: (952) 435-6287